REGULATED INFORMATION
GHENT, Belgium, 24 July 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 19.833 common shares have been issued by the Company in exchange for €121.444 as the result of the exercise of warrants.
As a result of this transaction, Ablynx now has 61.153.032 shares outstanding.
The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights currently is 2.860.214 which equals the total number of voting rights that may result from the exercise of these warrants. Currently 1.000 convertible bonds are outstanding entitling the holders thereof to 7.733.952 shares of the Company in the aggregate, upon conversion of such convertible bonds.
About Ablynx
Ablynx (http://www.ablynx.com/) is a biopharmaceutical company engaged in the development of Nanobodies (http://www.ablynx.com/technology-innovation/understanding-nanobodies/), proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes (http://www.ablynx.com/rd-portfolio/overview/) in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com (http://www.ablynx.com).
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com (mailto:edwin.moses@ablynx.com)
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste@ablynx.com (mailto:lies.vanneste@ablynx.com)
Follow us on Twitter @AblynxABLX (https://twitter.com/AblynxABLX)
Ablynx media/analyst relations
FTI Consulting:
Julia Phillips, Brett Pollard, Mo Noonan
t: +44 20 3727 1000
e: ablynx@fticonsulting.com (mailto:ablynx@fticonsulting.com)
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire
